Authors
Yasushi Ino, Rebecca A Betensky, Magdalena C Zlatescu, Hikaru Sasaki, David R Macdonald, Anat O Stemmer-Rachamimov, David A Ramsay, J Gregory Cairncross, David N Louis
Publication date
2001/4/1
Journal
Clinical Cancer Research
Volume
7
Issue
4
Pages
839-845
Publisher
American Association for Cancer Research
Description
Purpose: In a prior study of anaplastic oligodendrogliomas treated with chemotherapy at diagnosis or at recurrence after radiotherapy, allelic loss of chromosome 1p correlated with better chemotherapeutic response and overall survival. However, in this group of patients in whom therapeutic management was not uniform, loss of 1p did not identify all chemosensitive tumors, nor did all patients whose tumors harbor a 1p loss have long survival.
Experimental Design: To clarify the clinical relevance of molecular genetic testing at the time of diagnosis for patients with anaplastic oligodendrogliomas, we studied a larger, more homogeneous group of 50 patients with histologically defined anaplastic oligodendrogliomas treated with a chemotherapeutic regimen as the principal initial therapy.
Results: We demonstrate that these tumors can be divided genetically into four therapeutically and …
Total citations
20012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202410294463565341294026322118132111771048541
Scholar articles